{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:56:41Z","timestamp":1792155401456,"version":"4.4.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09838-6","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:46:05Z","timestamp":1781167565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incremental value of non-pharmacokinetic adherence measures for dapivirine vaginal ring use in resource limited setting"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6770-5588","authenticated-orcid":false,"given":"Andrew Max","family":"Abaasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Kusemererwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"9838_CR1","unstructured":"UNAIDS. The urgency of now: AIDS at a crossroads. Geneva: Joint United Nations Programme on HIV\/AIDS. 2024. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"9838_CR2","unstructured":"WHO. HIV and AIDS key facts July 2024. Available at https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids. Accessed on 18 Nov 2024."},{"key":"9838_CR3","unstructured":"WHO. Available at https:\/\/www.who.int\/news\/item\/26-01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection. Accessed on 08 Nov 2024."},{"key":"9838_CR4","doi-asserted-by":"crossref","unstructured":"B\u00e4rnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis. 2011;11(12):942\u201351.","DOI":"10.1016\/S1473-3099(11)70181-5"},{"key":"9838_CR5","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10461-017-1951-y","volume":"22","author":"A Abaasa","year":"2018","unstructured":"Abaasa A, Hendrix C, Gandhi M, Anderson P, Kamali A, Kibengo F, et al. Utility of different adherence measures for PrEP: patterns and incremental value. AIDS Behav. 2018;22:1165\u201373.","journal-title":"AIDS Behav"},{"issue":"22","key":"9838_CR6","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, van Niekerk N, Kapiga S, Bekker L-G, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133\u201343.","journal-title":"N Engl J Med"},{"key":"9838_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10461-018-2177-3","volume":"22","author":"S Kusemererwa","year":"2018","unstructured":"Kusemererwa S, Abaasa A, Onyango M, Nel AM, Isaacs M, Asiki G. Contraceptive preference among women at risk of HIV acquisition in a preparatory screening study for a phase III microbicide trial in South Western Uganda. AIDS Behav. 2018;22:131\u20138.","journal-title":"AIDS Behav"},{"issue":"4","key":"9838_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/QAI.0000000000000993","volume":"72","author":"DT Dimitrov","year":"2016","unstructured":"Dimitrov DT, M\u00e2sse BR, Donnell D. PrEP adherence patterns strongly affect individual HIV risk and observed efficacy in randomized clinical trials. JAIDS J Acquir Immune Defic Syndr. 2016;72(4):444\u201351.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"5","key":"9838_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048478","volume":"12","author":"EO Murchu","year":"2022","unstructured":"Murchu EO, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12(5):e048478.","journal-title":"BMJ Open"},{"key":"9838_CR10","doi-asserted-by":"crossref","unstructured":"Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. JAIDS J Acquir Immune Defic Syndr. 2014;66(3):324\u201331.","DOI":"10.1097\/QAI.0000000000000158"},{"key":"9838_CR11","unstructured":"Akello D. Adherence levels and associated factors to Pre-exposure prophylaxis among high risk individuals enrolled at public health facilities in Mbale district: Makerere University. 2019."},{"issue":"3","key":"9838_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-077733","volume":"14","author":"A Rathbone","year":"2024","unstructured":"Rathbone A, Cartwright N, Cummings L, Noble R, Budaiova K, Ashton M, et al. Exploring young people\u2019s attitudes to HIV prevention medication (PrEP) in England: a qualitative study. BMJ Open. 2024;14(3):e077733.","journal-title":"BMJ Open"},{"issue":"5","key":"9838_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036737","volume":"7","author":"JE Haberer","year":"2012","unstructured":"Haberer JE, Kiwanuka J, Nansera D, Ragland K, Mellins C, Bangsberg DR. Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PLoS ONE. 2012;7(5):e36737.","journal-title":"PLoS ONE"},{"issue":"11","key":"9838_CR14","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1080\/09540121.2012.687816","volume":"24","author":"A Kagee","year":"2012","unstructured":"Kagee A, Nel A. Assessing the association between self-report items for HIV pill adherence and biological measures. AIDS Care. 2012;24(11):1448\u201352.","journal-title":"AIDS Care"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09838-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09838-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09838-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:02:21Z","timestamp":1787050941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09838-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9838"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09838-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial involved human participants and the approval for its conduct was obtained from regulatory bodies of each participating country, Uganda: the Uganda Virus Research Institute Research Ethics Committee (Ref#-GC\/127\/13\/03\/33), the Uganda National Council of Science and Technology (Ref#- HS1362) and the National Drug Authority (Ref #-166\/ESR\/NDA\/DID-07\/2013). Before any trial procedures, written informed consent was obtained from each woman. Women that became HIV positive during the trial were referred to an HIV\/AIDS care provider of their choice in the community for treatment and care.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"536"}}